Summary In short: AOD 9604 is a promising fat-metabolism targeted peptide fragment of growth hormone designed to stimulate lipolysis and inhibit lipogenesis, while avoiding many of the typical growth-hormone side-effects
What is the standard GLOW dosage and frequency
Ness-Abramof R, Nabriski DA, Braverman LE, Shilo L, Weiss E, Reshef T, et al
Kannt & Pfenninger, Frontiers in Physiology emphasize that NAD preservation enhances oxidative metabolism, supporting sustained exercise capacity
However, headache incidence rates were similar between AOD-9604 and placebo groups, suggesting that many cases represented background occurrence rather than treatment-related effects
From a regulatory standpoint, neither retatrutide nor 5-Amino-1MQ holds a marketing authorisation in the UK